HIV/AIDS deaths in the U.S. have dropped significantly in recent years. In 1995, the death rate from HIV per 100,000 people was ****. That number has since decreased to *** per 100,000 as of 2023. The reduction in the HIV death rate in the U.S. can be attributed to an increase in access to HIV medications. HIV/AIDS in the U.S. Human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) cause a systemic viral infection that damages the immune system. AIDS is a syndrome that is caused by HIV. AIDS is when the immune system is severely weakened by HIV and the body can no longer fight off infections. Among all U.S. states, Georgia, followed by Florida and Louisiana, had the highest rates of new HIV diagnoses in 2022. HIV/AIDS treatments in the U.S. HIV/AIDS treatments include antiretroviral medications to reduce the levels of HIV within the body. The largest funders for HIV/AIDS medications and research are the National Institutes of Health (NIH) and the Ryan White Program. The top HIV drug worldwide, based on revenue generated in 2023 was Biktarvy. Around the world, access to antiretroviral treatment has increased dramatically in recent years, a huge step in reducing the number of HIV-related deaths. There is currently no cure for HIV.

In 2023, the death rate from HIV was highest among African Americans, with around 18 deaths per 100,000 population. This statistic shows the death rate from HIV in the U.S. in 2023, by race and ethnicity, per 100,000 population.

United States US: Prevalence of HIV: Total: % of Population Aged 15-49 data was reported at 0.500 % in 2014. This stayed constant from the previous number of 0.500 % for 2013. United States US: Prevalence of HIV: Total: % of Population Aged 15-49 data is updated yearly, averaging 0.500 % from Dec 2008 (Median) to 2014, with 7 observations. The data reached an all-time high of 0.500 % in 2014 and a record low of 0.500 % in 2014. United States US: Prevalence of HIV: Total: % of Population Aged 15-49 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Prevalence of HIV refers to the percentage of people ages 15-49 who are infected with HIV.; ; UNAIDS estimates.; Weighted Average;

The AIDS Public Information Data Set (APIDS) for years 1981-2002 on CDC WONDER online database contains counts of AIDS (Acquired Immune Deficiency Syndrome) cases reported by state and local health departments, by demographics; location (region and selected metropolitan areas); case-definition; month/year and quarter-year of diagnosis, report, and death (if applicable); and HIV exposure group (risk factors for AIDS). Data are produced by the US Department of Health and Human Services (US DHHS), Public Health Service (PHS), Centers for Disease Control and Prevention (CDC), National Center for HIV, STD and TB Prevention (NCHSTP), Division of HIV/AIDS Prevention (DHP).

Forecast: Estimated AIDS Deaths in United States 2023 - 2027 Discover more data with ReportLinker!

Forecast: HIV-AIDS Mortality in the US 2024 - 2028 Discover more data with ReportLinker!

These data were reported to the NYC DOHMH by March 31, 2021

This dataset includes data on new diagnoses of HIV and AIDS in NYC for the calendar years 2016 through 2020. Reported cases and case rates (per 100,000 population) are stratified by United Hospital Fund (UHF) neighborhood, sex, and race/ethnicity.

In 2023, the death rate from HIV was highest among those aged 60 to 64 years, with around **** deaths per 100,000 population. This statistic shows the death rate from HIV in the U.S. in 2023, by age, per 100,000 population.

Objective: To examine if the rankings of state HIV age-standardized death rates (ASDRs) changed if different standard population (SP) was used.

Design: A cross-sectional population-based observational study. Setting 36 states in the United States.

Participants: People died from 2015 to 2019.

Main outcome measures: State HIV ASDR using 4 SPs, namely WHO2000, US2000, US2mor020, and Eur2011–2030.

Results: The rankings of 19 states did not change when ASDRs were calculated using US2000 and US2020. Of the 17 states whose rankings changed, the rankings of 9 states calculated using US2000 were higher than those calculated using US2020; in 8 states, the rankings were lower. The states with the greatest changes in rankings between US2000 and US2020 were Kentucky (12th and 9th, respectively) and Massachusetts (8th and 11th, respectively).

Conclusions: State ASDRs calculated using the current official SP (US2000) weigh middle-age HIV death rates more heavily than older-age HIV death rates, resulting in lower ASDRs among states with higher older-age HIV death rates.

BackgroundCombination antiretroviral therapy (ART) has significantly increased survival among HIV-positive adults in the United States (U.S.) and Canada, but gains in life expectancy for this region have not been well characterized. We aim to estimate temporal changes in life expectancy among HIV-positive adults on ART from 2000–2007 in the U.S. and Canada.MethodsParticipants were from the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), aged ≥20 years and on ART. Mortality rates were calculated using participants' person-time from January 1, 2000 or ART initiation until death, loss to follow-up, or administrative censoring December 31, 2007. Life expectancy at age 20, defined as the average number of additional years that a person of a specific age will live, provided the current age-specific mortality rates remain constant, was estimated using abridged life tables.ResultsThe crude mortality rate was 19.8/1,000 person-years, among 22,937 individuals contributing 82,022 person-years and 1,622 deaths. Life expectancy increased from 36.1 [standard error (SE) 0.5] to 51.4 [SE 0.5] years from 2000–2002 to 2006–2007. Men and women had comparable life expectancies in all periods except the last (2006–2007). Life expectancy was lower for individuals with a history of injection drug use, non-whites, and in patients with baseline CD4 counts <350 cells/mm3.ConclusionsA 20-year-old HIV-positive adult on ART in the U.S. or Canada is expected to live into their early 70 s, a life expectancy approaching that of the general population. Differences by sex, race, HIV transmission risk group, and CD4 count remain.

UNAIDS estimated that there were some ******* people worldwide that died from acquired immune deficiency syndrome (AIDS) in 2024. This statistic depicts the total number of annual AIDS-related deaths worldwide from 2000 to 2024. HIV/AIDS burden A majority of countries with the highest burden due to HIV and AIDS are in Africa- in 2024, the highest number of AIDS-related deaths occurred in South Africa and Mozambique and the highest prevalence of HIV was found in Eswatini. Although access to life-saving antiretroviral therapy treatment (ART) has increased globally over recent years, many individuals living with HIV still lack access to ART. Barriers and interventions In part due to the development of ART, the number of people living with HIV worldwide is continuing to increase, reaching almost ** million in 2024. Important public health measures to combat the burden of the disease include a combination of biomedical and behavioral interventions such as pre- and post-exposure prophylaxis, and context-specific structural interventions to reduce barriers to supplies and education. One prominent barrier faced by those living with HIV is stigma, which can often cause disadvantages in many areas of life, including employment, use of health services, and social support.

Average number IDU living with AIDS, number of AIDS deaths, and AIDS mortality rates of IDUs living with AIDS per 10,000 adult population (age 15–64) in 86 large metropolitan statistical areas in the USA 1993–1995 (Pre-HAART) and 2004–2006 (HAART era), and the AIDS mortality rate ratio between late and early years.

Users can access population data related to the screening, prevalence, and incidence of HIV and AIDS in the United States. Background The HIV/AIDS Statistics and Surveillance data is maintained by the Centers for Disease Control. Annual reports, fact sheets, slide sets, and basic statistics are available in a variety of formats. Fact sheets are available for a variety of subgroups including but not limited to examining HIV prevalence among different races, ages, and sexual orientations. Slide sets looking at HIV and AIDS prevalence among different groups and different regions are also available. The HIV Surveillance Report is available on an annual basis. User functionality Data is presented in report or fact sheet format and can be downloaded in PDF or HTML formats. Slide sets are available in PDF or PowerPoint format. Basic statistics and other information is avaible in HTML format. Data Notes The data sources are clearly referenced for each report, chart, and fact sheet. The most recent data is from 2009. Reports are published annually in the late summer or early fall

This is the replication kit for "Evidence and Lessons on the Health Impacts of Public Health Funding from the Fight against HIV/AIDS". HIV/AIDS has been one of the largest public health crises in recent history, and the U.S. federal government has spent hundreds of billions of dollars fighting the disease. This study examines the impact of the large amounts of federal funding allocated to U.S. cities to combat HIV/AIDS through the Ryan White CARE Act's first title. The findings indicate that the cost to avoid an HIV/AIDS death through the program is roughly $334,000, that the program has saved approximately 57,000 lives through 2018, and that funding disparities are responsible for the uneven progress in combating HIV/AIDS across the United States.

United States US: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data was reported at 14.600 % in 2016. This records an increase from the previous number of 14.300 % for 2015. United States US: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data is updated yearly, averaging 14.600 % from Dec 2000 (Median) to 2016, with 5 observations. The data reached an all-time high of 18.000 % in 2000 and a record low of 14.300 % in 2015. United States US: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).; ; World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).; Weighted Average;

United States US: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data was reported at 11.800 NA in 2016. This records an increase from the previous number of 11.600 NA for 2015. United States US: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data is updated yearly, averaging 11.800 NA from Dec 2000 (Median) to 2016, with 5 observations. The data reached an all-time high of 14.600 NA in 2000 and a record low of 11.600 NA in 2015. United States US: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s United States – Table US.World Bank.WDI: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).; ; World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).; Weighted average;

In January 2025, President Trump ordered a pause on funding for the U.S. Agency for International Development (USAID) and a 90-day review of all U.S. foreign assistance. By the end of March, the review had been completed, 83 percent of USAID programs were terminated, and it was announced that certain USAID functions would be overtaken by the Department of State while all others would be discontinued. A preprint research paper posted in April 2025 looked at the possible effects that reductions or cessation of U.S. foreign aid would have on global health. The researchers estimated that the elimination of U.S. foreign aid for global health would result in an additional 15.2 million AIDS-related deaths from 2025 to 2040. Furthermore, they estimated that the loss of U.S. aid would lead to 26.2 million additional HIV infections over this period. This paper has not been peer-reviewed so the estimates should be interpreted with caution, but there is no doubt that such cuts to U.S. foreign aid will result in an increase in HIV infections and deaths, especially in high-impact countries. Trump has said that the United States spends too much on foreign aid and accused USAID of being corrupt and a waste of money. However, foreign aid accounts for just one percent of the federal budget. Furthermore, it is predicted that millions of people will die due to the dissolution of USAID, as vulnerable people around the world will no longer be able to access prevention and treatment for diseases such as HIV/AIDS, tuberculosis, and malaria.

IntroductionMozambique continues to face a severe HIV epidemic and high cost for its control, largely born by international donors. We assessed feasible targets, likely impact and costs for the 2015–2019 national strategic HIV/AIDS plan (NSP).MethodsThe HIV epidemic and response was modelled in the Spectrum/Goals/Resource Needs dynamical simulation model, separately for North/Center/South regions, fitted to antenatal clinic surveillance data, household and key risk group surveys, program statistics, and financial records. Intervention targets were defined in collaboration with the National AIDS Council, Ministry of Health, technical partners and implementing NGOs, considering existing commitments.ResultsImplementing the NSP to meet existing coverage targets would reduce annual new infections among all ages from 105,000 in 2014 to 78,000 in 2019, and reduce annual HIV/AIDS-related deaths from 80,000 to 56,000. Additional scale-up of prevention interventions targeting high-risk groups, with improved patient retention on ART, could further reduce burden to 65,000 new infections and 51,000 HIV-related deaths in 2019. Program cost would increase from US$ 273 million in 2014, to US$ 433 million in 2019 for ‘Current targets’, or US$ 495 million in 2019 for ‘Accelerated scale-up’. The ‘Accelerated scale-up’ would lower cost per infection averted, due to an enhanced focus on behavioural prevention for high-risk groups. Cost and mortality impact are driven by ART, which accounts for 53% of resource needs in 2019. Infections averted are driven by scale-up of interventions targeting sex work (North, rising epidemic) and voluntary male circumcision (Center & South, generalized epidemics).ConclusionThe NSP could aim to reduce annual new HIV infections and deaths by 2019 by 30% and 40%, respectively, from 2014 levels. Achieving incidence and mortality reductions corresponding to UNAIDS’ ‘Fast track’ targets will require increased ART coverage and additional behavioural prevention targeting key risk groups.

This dataset contains estimates for age-standardized mortality rates from lower respiratory infections (LRIs), diarrheal diseases, HIV/AIDS, meningitis, hepatitis, and tuberculosis between 1980 t0 2014.

In 2024, Suriname was the country with the highest number of deaths per thousand people due to HIV/AIDS in Latin America and the Caribbean, with an estimate of **** deaths per 1,000 people. Belize followed, with around **** deaths per 1,000 people. That year, the Latin American country with the highest number of people living with HIV was Brazil.